

UNITED STATES INTERNATIONAL TRADE COMMISSION

Washington, D.C.

In the Matter of

**CERTAIN DERMATOLOGICAL
TREATMENT DEVICES AND
COMPONENTS THEREOF**

Inv. No. 337-TA-1356

**NOTICE: ISSUANCE OF INITIAL DETERMINATION ON
VIOLATION OF SECTION 337 WITH RECOMMENDATION ON
REMEDY AND BOND**

(December 19, 2024)

The Final Initial Determination (“ID”) on Violation of Section 337 of the Tariff Act, as amended, 19 U.S.C. § 1337 (“Section 337”), has been issued today.

It is a finding of the ID that Complainant Serendia, LLC (“Complainant” or “Serendia”) has proven by a preponderance of evidence that Respondents Jeisys Medical Inc., Cynosure, LLC, EndyMed Medical, Ltd., and EndyMed Medical Inc. (collectively, “Respondents”) have violated subsection (b) of Section 337 of the Tariff Act of 1930, in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain dermatological treatment devices and components thereof.¹

¹ On December 9, 2024, Complainant Serendia, LLC (“Serendia”), and Respondents Jeisys Medical Inc. and Cynosure, LLC (collectively, “Respondents Jeisys and Cynosure,” and with Serendia, the “Moving Parties”), filed a joint unopposed motion to suspend remaining Procedural Schedule deadlines in this Investigation (“Motion to Suspend”) with respect to them, in view of the Moving Parties’ pending motion to terminate Respondents Jeisys and Cynosure from this Investigation due to settlement. (Motion Docket No. 1356-043 (Dec. 9, 2024)). The Motion to Suspend was granted. (*See* Order No. 63 (Dec. 10, 2024)). The Moving Parties stated that they “anticipate filing a joint motion to terminate the Investigation pursuant to Commission Rule 210.21(b) no later than December 23, 2024, pursuant to the terms of the settlement agreement.” (Mot. to Suspend at 1.). On December 13, 2024, the Moving Parties filed the motion to terminate Respondents Jeisys and Cynosure due to settlement (“Motion to Terminate”). (Motion Docket No. 1356-044 (Dec. 13, 2024)). The Motion to Terminate was granted. (*See* Order No. 64 (Dec. 18, 2024)). The Moving Parties have known since approximately September 9, 2024, and then

It is a finding of the ID that Respondents have infringed asserted claims 1, 9, and 22 of U.S. Patent No. 9,480,836 (“the ’836 patent”). It is also a finding of the ID that the asserted claims of the ’836 patent are valid.

It is a finding of the ID that Respondents have infringed asserted claims 11 and 16 of U.S. Patent No. 9,320,536 (“the ’536 patent”). It is also a finding of the ID that the asserted claims of the ’536 patent are valid.

It is a finding of the ID that Respondents have infringed asserted claim 14 of U.S. Patent No. 9,775,774 (“the ’774 patent”). It is also a finding of the ID that the asserted claims of the ’774 patent are valid.

It is a finding of the ID that Respondents have infringed asserted claims 5, 13, and 18 of U.S. Patent No. 10,869,812 (“the ’812 patent”). It is also a finding of the ID that the asserted claims of the ’812 patent are valid.


It is a finding of the ID that one or more of Serendia’s domestic industry products have satisfied the technical industry prong of the domestic industry requirement for the ’836, ’536, ’774, and ’812 patents. It is also a finding of the ID that Serendia has satisfied the economic prong of the domestic industry requirement under Section 337(a)(3)(B).

Accordingly, the ID recommends: (1) a Limited Exclusion Order with a standard

were notified again last week, that the ID would be issued by December 20, 2024. The Moving Parties then filed their Motion to Terminate. Given the timing, the Motion to Terminate will not have been addressed by the Commission by the time the ID will be issued. As a result, the analyses and determinations contained in the ID with respect to Respondents Jeisys and Cynosure have not been deleted. Once their Motion to Terminate has been addressed by the Commission, and Respondents Jeisys and Cynosure are no longer parties in this Investigation, Respondents Jeisys and Cynosure’s accused products will no longer be at issue in this Investigation and will not be subject to any determinations set forth in the ID, including recommendations on remedy and bond. Respondents EndyMed Medical, Ltd. and EndyMed Medical Inc. are not a party to the settlement agreement and remain as the only respondents in this Investigation. (Mot. to Suspend at 2; Mot. to Terminate at 4-5.). Other named respondents previously settled with Serendia, as noted in the Selected Procedural History of the ID, which will issue following the Notice of Issuance. *See Certain Dermatological Treatment Devices and Components Thereof*, Inv. No. 337-TA-1356, Initial Determination at Section II.A (Dec. 19, 2024).

certification provision; (2) Cease and Desist Orders against Cynosure and EndyMed; and (3) that a bond be entered during the Presidential Review Period.

SO ORDERED.


MaryJoan McNamara
Administrative Law Judge